AI in Oncology: Current and Future Applications
AI has been used in oncology for years, but recent studies suggest AI could have many additional applications in cancer care.
AI has been used in oncology for years, but recent studies suggest AI could have many additional applications in cancer care.
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Aphexda (motixafortide) is expected to be available later this month.
Patients from racial and ethnic minority groups are still underrepresented in cancer research, despite efforts to make clinical trials more diverse.
Melflufen plus daratumumab and dexamethasone produced better outcomes than daratumumab alone in a phase 3 trial of patients with relapsed/refractory multiple myeloma.
The combination of oral mezigdomide and dexamethasone has shown activity in patients with relapsed/refractory multiple myeloma.
About 1 in 5 immunosuppressed individuals have no detectable IgG anti-spike antibodies after 3 or more COVID-19 vaccinations, a new study suggests.
Some cancer centers have lifted mask mandates that were intended to protect patients from COVID-19, despite patient concerns.
Cancer survivors with functional disabilities have higher health care usage and medical costs than survivors without disabilities, data suggest.
Black patients are underrepresented in studies of multiple myeloma used to support IMWG guidelines, researchers found.